January 17, 2018 06:15 AM EST

Kymriah gets speedy reviews in US and EU as Novartis looks to swiftly expand CAR-T indications

Amber Tong

Equipped with data to directly compete with Gilead’s $GILD CAR-T, Novartis has secured promises of quick reviews of Kymriah for a second indication in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kymriah gets speedy reviews in US and EU as Novartis looks to swiftly expand CAR-T indications

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

Takeda scraps programs as it raises full-year guidance

Cargo Therapeutics cuts lead CAR-T program, 50% of staff

Rentschler exits cell and gene business due to low demand, will prioritize biologics

Roche aims for derisked deals and ruthless portfolio cuts in 2025

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

Kym­ri­ah gets speedy re­views in US and EU as No­var­tis looks to swift­ly ex­pand CAR-T in­di­ca­tions

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Kymriah gets speedy reviews in US and EU as Novartis looks to swiftly expand CAR-T indications